Iroko's acute pain drug Zorvolex wins FDA approval

10/21/2013 | Reuters

Iroko Pharmaceuticals' nonsteroidal anti-inflammatory drug Zorvolex, or diclofenac, was approved by the FDA for treatment of adults with mild to moderate acute pain. Zorvolex was cleared at a 20% lower dose strength than currently available treatments, reducing the risk of strokes, acute renal failures and other serious adverse events.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC